A Phase 3 interventional study of Docetaxel and ZD4054 in Prostate Cancer, sponsored by AstraZeneca. Completed at 147 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 5th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 18th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Australia, Germany and 4 more countries
Ages 18–99 · Men only
AstraZeneca · Sites in United States, Australia, Korea, Republic of
Ages 18–100 · Men only
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Brazil, China and 7 more countries
Ages 18–130 · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 17 · Phase 4 4
First in 1994; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,494 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 60 interventional studies, 310 across the 29 observational. Of the 58 that completed or were terminated, 11 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Prostatic Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06267729AstraZenecaStudy of AZD0754 in Participants With Metastatic Prostate Cancer | 2026-11-24 |
| NCT06402331Fusion Pharmaceuticals Inc.FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2026-12-23 |
| NCT06380738AstraZenecaReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | 2027-02-14 |
| NCT07560215AstraZenecaPROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Enthuse M1C is a large phase III clinical trial studying the safety and efficacy of ZD4054 (Zibotentan) in combination with docetaxel (Taxotere) in patients with metastatic hormone resistant prostate cancer (HRPC).
This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can further improve survival compared with docetaxel alone.
ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin A receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer patients with bone metastases compared with docetaxel.
All patients participating in this clinical trial will receive docetaxel chemotherapy, which is a commonly used chemotherapy to treat prostate cancer in addition to other existing prostate cancer therapies.
Half the patients will receive ZD4054 (Zibotentan), and half the patients will receive placebo in addition to docetaxel and other prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may further slow the progression of the tumour.
No patients will be deprived of standard prostate cancer therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who answer TRUE to the following criteria may be eligible to participate in this trial.
Exclusion Criteria:
Patients who answer TRUE to the following ARE NOT eligible to participate in this trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
Drug: Docetaxel · Drug: Placebo
ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
Drug: Docetaxel · Drug: ZD4054
Overall Survival
Median time (in months) from randomisation until death using the Kaplan-Meier method.
Time frame: Patients were followed for survival up to 40 months
Progression Free Survival
Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
Time frame: Patients were followed for progression up to 40 months
Incidence of Skeletal Related Events
Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Time to Prostate-specific Antigen (PSA) Progression
Median time (in months) from randomisation until first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Time to Pain Progression
Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Pain Response
Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
Health Related Quality of Life
Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
PSA Response
PSA response defined as \>50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.
Time frame: While receiving docetaxel study visits were aligned with its administration ie every 3weeks, after 12 weeks and completion of docetaxel therapy every 12 weeks (up to 40 months)
1494 patients with hormone resistant prostate cancer patients and bone metastasis were recruited between 24th January 2008 and 10th May 2011
| Milestone | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Started | 524 | 528 |
| Patients who received ip | 522 | 525 |
| Completed | 94 | 77 |
| Not completed | 430 | 451 |
| Withdrew: Withdrawal by subject | 71 | 77 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Adverse event | 87 | 76 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Reason not otherwise captured, eg; death | 265 | 290 |
| Withdrew: Patients randomized but not treated | 2 | 3 |
Median time (in months) from randomisation until death using the Kaplan-Meier method.
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Overall Survival | 20.0 (11.6 to 32.0) | 19.2 (12.0 to 30.3) |
Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Progression Free Survival | 7.0 (3.5 to 13.1) | 7.9 (4.0 to 12.6) |
Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Incidence of Skeletal Related Events | 17.4 (10.0 to 25.3) | 17.3 (10.3 to 26.0) |
Median time (in months) from randomisation until first PSA value \>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 11.9 (6.2 to 19.6) | 12.1 (6.0 to 18.3) |
Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Time to Pain Progression | 9.3 (3.9 to 18.4) | 10.0 (4.2 to 18.6) |
Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.
| Participants | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Pain Response | 255 | 276 |
Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.
| Months | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Health Related Quality of Life | 4.4 (1.6 to 10.7) | 5.1 (2.1 to 12.0) |
PSA response defined as \>50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.
| Participants | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| PSA Response | 279 | 298 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZD4054 + Docetaxel | — | 214/522 (41%) | 490/522 (93.9%) |
| Placebo + Docetaxel | — | 203/525 (38.7%) | 483/525 (92%) |
| Event | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| PneumoniaInfections and infestations | 26/522 | 8/525 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 22/522 | 16/525 |
| AnaemiaBlood and lymphatic system disorders | 19/522 | 8/525 |
| NeutropeniaBlood and lymphatic system disorders | 10/522 | 12/525 |
| PyrexiaGeneral disorders | 6/522 | 12/525 |
| DeathGeneral disorders | 10/522 | 6/525 |
| SepsisInfections and infestations | 10/522 | 2/525 |
| Urinary Tract InfectionInfections and infestations | 9/522 | 7/525 |
| DehydrationMetabolism and nutrition disorders | 7/522 | 8/525 |
| Renal Failure AcuteRenal and urinary disorders | 7/522 | 2/525 |
| Event | ZD4054 + Docetaxel | Placebo + Docetaxel |
|---|---|---|
| Oedema PeripheralGeneral disorders | 278/522 | 188/525 |
| AlopeciaSkin and subcutaneous tissue disorders | 178/522 | 196/525 |
| DiarrhoeaGastrointestinal disorders | 183/522 | 185/525 |
| NauseaGastrointestinal disorders | 174/522 | 160/525 |
| FatigueGeneral disorders | 150/522 | 164/525 |
| AnaemiaBlood and lymphatic system disorders | 155/522 | 116/525 |
| ConstipationGastrointestinal disorders | 152/522 | 129/525 |
| Decreased AppetiteMetabolism and nutrition disorders | 127/522 | 119/525 |
| AstheniaGeneral disorders | 118/522 | 117/525 |
| NeutropeniaBlood and lymphatic system disorders | 114/522 | 118/525 |
| Age Continuous(years) | ZD4054 + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| overall | 8.1 ± 67.7 | 7.8 ± 67.6 | 7.9 ± 67.6 |
| Sex: Female, Male(Participants) | ZD4054 + Docetaxel | Placebo + Docetaxel | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 524 | 528 | 1052 |
Showing the first 100 of 147 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2008, a primary completion of May 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054